Related Experiment Video
Updated: Jun 26, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Effects of omeprazole on plasma levels of raltegravir
Marian Iwamoto1, Larissa A Wenning, Bach-Yen Nguyen
1Merck & Co., Whitehouse Station, Rahway, NJ 07065-0900, USA. marian_iwamoto@merck.com
Abstract:
Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with omeprazole coadministration in healthy subjects; this is likely secondary to an increase in bioavailability attributable to increased gastric pH. Increased gastric pH has been reported in HIV-1-infected individuals, and the effects of omeprazole in this intended population may be diminished. Further investigation is necessary.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Bioavailability: Influencing Factors
Time Course of Drug Effect
